Genomic, Proteomic, and Phenotypic Spectrum of Novel O-Sialoglycoprotein Endopeptidase Variant in Four Affected Individuals With Galloway-Mowat Syndrome

Galloway-Mowat syndrome is a rare autosomal recessive disease characterized by a unique combination of renal and neurological manifestations, including early-onset steroid-resistant nephrotic syndrome, microcephaly, psychomotor delay, and gyral abnormalities of the brain. Most patients die during early childhood. Here, we identified a novel homozygous O-sialoglycoprotein endopeptidase (OSGEP) variant, NM_017807.3:c.973C>G (p.Arg325Gly), in four affected individuals in an extended consanguineous family from Saudi Arabia. We have described the detailed clinical characterization, brain imaging results, and muscle biopsy findings. The described phenotype varied from embryonic lethality to early pregnancy loss or death at the age of 9. Renal disease is often the cause of death. Protein modeling of this OSGEP variant confirmed its pathogenicity. In addition, proteomic analysis of the affected patients proposed a link between the KEOPS complex function and human pathology and suggested potential pathogenic mechanisms.

Recently, Braun et al. (2017) identified novel causative variants in four genes encoding the four "kinase, endopeptidase, and other proteins of small size" (KEOPS) subunits: OSGEP, TP53RK, TPRKB, and LAGE3, in 37 individuals from 32 families with GAMOS (Braun et al., 2017). OSGEP encodes the tRNA N6-adenosine threonylcarbamoyltransferase protein (OSGEP), a subunit of the highly conserved KEOPS complex. The KEOPS complex controls the universal chemical change of tRNAs essential for translational accuracy. It has been implicated in telomere-associated DNA damage response (DDR) signaling and exhibits intrinsic DNA binding ability (Braun et al., 2017). Braun et al. (2017) knocked down genes encoding KEOPS subunits in human podocytes, resulting in impaired cell proliferation, translational attenuation, endoplasmic reticulum stress, activation of DDR signaling, increased apoptosis, and defects in actin regulation, which are possible pathogenic features of GAMOS (Braun et al., 2017). Independently, another study by Edvardson et al. (2017) reported a familial case of GAMOS with a homozygous OSGEP variant.
Here, we report genetic and proteomic data and the clinical characterization of an extended family with four affected members with GAMOS.

CLINICAL REPORT
The parents of the patients were first cousins of Saudi origin. They have seven offsprings, three of whom exhibited strikingly similar phenotypes (II-1, II-2, and II-8) (Figure 1), and three spontaneous miscarriages. Table 1 summarizes the clinical features of the affected individuals.

Patient II-1
The male baby was the first offspring of the family. No perinatal or neonatal problems were observed. The birth weight was 3.0 kg. He developed seizure and periorbital edema at 3 years of age and exhibited abnormal facial features ( Figure 1). Considerable proteinuria was observed, and the patient was diagnosed with nephrotic syndrome and treated conservatively. MRI brain abnormalities are shown in Figure 2. He died at 9 years of age and had end-stage renal disease.

Patient II-2
The female baby was the second offspring of the family. No perinatal or neonatal problems were observed. The birth weight was 3.5 kg. She developed the same symptoms as her brother, starting at 2.5 years of age, and died at the age of 6 with respiratory insufficiency, pulmonary edema, and cardiac tamponade. This patient underwent two muscle biopsies for diagnostic purposes. The first was performed during her third year. It showed mild variation in fiber size and rare degenerating fibers. NADH and SDH showed preservation of intermyofibrillar sarcoplasmic architecture. Few fibers showed some degree of increased activity of the oxidative enzymes. COX stain was reported to be negative in the majority of the myofibers. The second muscle biopsy (Figure 1) was performed at the age of six. The variation in this biopsy was prominent, with multiple small-sized muscle fibers and a focal increase of the perimysial connective tissue in the form of increased fat deposition or mild fibrosis. However, the endomysial fibrosis was mild and focal. Like the previous biopsy, the intermyofibrillar architecture using NADH and SDH stains was relatively preserved with a focal increase of the activity of oxidative enzymes. Electron microscopy was performed on the second sample and showed a slightly increased number of mitochondria. No structural changes, nemaline bodies, or intramitochondrial inclusions were documented. Both samples lacked evidence of inflammation or structural abnormalities. Trichrome staining did not reveal evidence of ragged red fibers. Fiber type grouping using ATPases showed a normal mosaic pattern of fiber types with no evidence of grouping or selective fiber type atrophy.

Patient II-8
This male patient was born at 37 weeks of gestation via emergency Cesarean section (C/S) due to previous C-section deliveries, with a birth weight of 2.7 kg, length of 48 cm, and head circumference (HC) of 30.5 cm (<3rd percentile). The Apgar scores at 1 and 5 min were 8 and 9, respectively. Soon after birth, the baby was admitted to the neonatal intensive care unit for hypoglycemia and respiratory distress, which was managed by Survanta ® via an endotracheal tube. He was then extubated and treated with a continuous positive airway pressure  machine. After significant improvement, the patient was discharged in good health after 7 days. His mother noticed some dysmorphic facial features similar to those of his deceased siblings ( Figure 1). Initially, the patient did not have any symptoms, but the mother noticed delayed development. He started cruising at 1.5 years and walked with support at 1.8 years. He exhibited a delay in expressive language and communicated by pointing or facial/body gestures. He could say "mama" and "baba," using the words appropriately for the parents but could not speak more words. He was able to follow simple one-step commands. At 4 years of age, he developed generalized spasticity with impaired mobility. There were no seizures, abnormal movements, or changes in consciousness or behavior. He was able to self-feed.
Physical examination revealed that apart from the previously mentioned dysmorphic features, generalized spasticity occurred all over the body, more in the lower limbs. Along with central hypotonia, the lower limb showed fixed flexion at the knee and ankle joints and flattening of the foot arches. Brisk deep tendon reflexes were also observed. At this point, different specialties, including pediatrics, neurology, ophthalmology, genetics, and metabolism were involved in caring for this patient for further assessment and evaluation. Laboratory investigations revealed hypoalbuminemia and hypomagnesemia with normal calcium levels, normal total creatine kinase, thyroid panel, ammonia, lactic acid, and metabolic screening. Urinalysis showed 3 + proteinuria, no hematuria, normal cell counts in urine, and normal renal function. EEG was normal. The 46XY karyotype was normal. The renal ultrasonography findings were unremarkable. Figure 2 shows brain MRI, which revealed bilaterally symmetrical T2/flair hyperintensity and diffusion restriction in the periventricular white matter and dorsal brain stem with normal spectroscopy, suggestive of metachromatic leukodystrophy. These findings were similar to the synthesis defect of T6 modification of tRNAs, addressed by Edvardson et al. (2017) and Braun et al. (2017).

Patient IV-1
She is the first baby of the young Saudi cousin-couple. She was an 18month-old girl born at full term via normal spontaneous vaginal delivery (NSVD), with a birth weight of 3 kg, length of 48 cm, and HC of 34.5 cm. The Apgar scores at 1 and 5 min were 8 and 9, respectively. The patient was discharged in good health on the second day. She developed well, and her growth parameters at the age of 14 months were a weight of 11 kg (>75th centile), height 81 cm (>75th centile), and HC 44.5 cm (between the 10th and 25th centile). She received all the vaccines and follow-up care at a general pediatric clinic. Thereafter, her family started noticing some facial dysmorphic features similar to those of the affected cousins ( Figure 1). However, she was asymptomatic at this age. Routine laboratory testing revealed proteinuria in urinalysis (++) (100-200), low albumin at 30 g/L, with normal prealbumin of 0.3 g/L, CBC differential, liver function test, electrolytes, blood gas, and renal profile. An MRI demonstrated similar imaging findings consisting of mild atrophy of the cerebellum normal corpus callosum, brainstem, and upper cervical spinal cord and also mild high signal intensity in the periventricular and deep white matter, sparing the subcortical white matter. There is mild cerebral and cerebellar atrophy ( Figure 2C). Global parenchymal volume loss is seen in all patients.

Human Subjects
All patients underwent complete clinical evaluation of the GAMOS phenotype. Standard clinical exome consent was used for wholeexome sequencing of the whole family in the clinical laboratory. The parents signed an informed consent form. Ethical approval for clinical and laboratory data collection was obtained from King Saudi University (KSU) in Riyadh, Saudi Arabia, under protocol number Ref. No.18/0093/IR. Blood was then collected from the subjects and the parents in EDTA-coated tubes for DNA extraction, and the skin biopsy sample was taken from the index patient (II-8) and a healthy sister for proteomic profiling. Table 1 summarizes the clinical features of the affected individuals.

Whole-Exome Sequencing
Whole-exome sequencing was performed for Patient II-8 as there were no DNA samples from the deceased siblings, patients II-1 and II-2. Approximately, 37 Mb (214,405 exons) of the consensus coding sequences were enriched from fragmented genomic DNA by >340,000 probes that were designed against the human genome (Nextera Rapid Capture Exome, Illumina, CA, United States). The generated library was sequenced on an Illumina NextSeq or platform (Illumina) to an average coverage depth of 70-100 ×. An end-to-end, in-house bioinformatics pipeline, including base calling, primary filtering of low-quality reads, probable artifacts, and annotation of variants, was applied.
All the disease-causing variants reported in HGMD ® , ClinVar and all variants with a minor allele frequency of less than 1% in the ExAc database were considered for this study. Our evaluation focused on the exons with intron boundaries of ±20. All relevant inheritance patterns were considered, and the family history and clinical information were used to evaluate the identified variants. Only variants related to the phenotype have been reported.

Computational Analysis of the Mutants
Protein modeling was performed to model the OSGEP amino acid variant exhibited by the patient. The crystal structure of the human probable tRNA N6-adenosine threonylcarbamoyltransferase (PDB accession number 6GWJ.1.C) was used as basis for modeling of the c.973C > G (p. Arg325Gly) variant using the Pymol program (pymol.org). Furthermore, in silico protein prediction algorithms (SIFT, PolyPhen, Mutation Taster) were used to predict the effect of selected mutation.

Tissue Collection and Fibroblast Culture
A dermal biopsy pinch was collected from each patient (GAMOS and control) and transferred to the research laboratory in a medium containing advanced RPMI (Gibco, 12633012, MA, United States) and 1% antibiotic-antimycotic solution (Gibco, 15240-062). The tissues were left in the medium for 1-2 h after collection. Skin mesenchymal stem cells were then isolated separately using the explant method, as previously described (Alfares et al., 2020). In brief, fat was removed from the dermal biopsies, the tissues were chopped and plated in a six-well plate, and three pieces of tissue were collected in one well of a six-well plate. The cells were left undisturbed for 4-6 days in the conditioned medium (growth-specific medium) comprising advanced RPMI (Gibco, 12633012), 5% fetal bovine serum (FBS) (Gibco, 10099141), 20 pg recombinant human fibroblast growth factor (rh-FGF) (Lonza, CC-4065J), 0.1% insulin (Gibco, 51500056), and 1% antibiotic-antimycotic solution.

Protein Extraction From Patient Cells
Proteins were extracted from triplicate biological samples of −2 × 10 6 cells/mL from each patient (both GAMOS and control) directly in lysis buffer (0.5 ml, 30 mM Tris buffer pH 8.8 containing 7 M urea, 2 M thiourea, 4% Chaps, 1X protease inhibitor mix). The suspension was shaken for 1 h at room temperature and then sonicated using a microsonicator (Qsonica Sonicators, CT, United States) at 30% pulse and two intervals of 1 min each, separated by a minute's gap on ice. Fifty millimolar dithiothreitol was then added, and the protein extracts were centrifuged at 20,000 × g for 1 h at 4°C. The pellets were then removed, and the solubilized proteins in the supernatants were precipitated using a 2D clean-up kit, according to the manufacturer's protocol (GE Healthcare, IL, United States). The pellet was then solubilized in labeling buffer (7 M urea, 2 M thiourea, 30 mM Tris-HCl, 4% CHAPS, pH 8.5). The concentration of protein samples was determined in triplicate using a 2D-Quant Kit (GE Healthcare, IL, United States) (Galloway and Mowat, 1968).

Fluorescence Labeling and Two-Dimensional Difference in Gel Electrophoresis
The extracted proteins (50 µg) from the patient's sample and control were labeled with Cy3 and Cy5, respectively. Labeling was performed for 30 min on ice in the dark. The reactions were quenched by adding 1 µl of lysine (10 mM) for 10 min on ice in the dark. An equal amount of each sample was pooled, labeled with Cy2, and used as an internal standard. A dye-switching strategy was applied during labeling to avoid dye-specific bias (Supplementary Table S1). One-dimensional analytical gel electrophoresis was performed, followed by two-dimensional difference in gel electrophoresis on 12.5% fixed concentration gels, as previously described (Cohen and Turner, 1994;Alfadda et al., 2013). After two-dimensional difference in gel electrophoresis (2D-DIGE), the gels were scanned on a Typhoon 9410 scanner with Ettan DALT gel alignment guides using excitation/emission wavelengths specific for Cy2 (488/ 520 nm), Cy3 (532/580 nm), and Cy5 (633/670 nm).

Bioinformatics Analysis: Pathway Analysis and Functional Classification of Proteins
The successfully identified proteins were uploaded into the ingenuity pathway analysis (IPA) software program (Ingenuity ® Systems, http://www.ingenuity.com). This program helps identify proteins and annotates them with related functions and pathways. The annotations were carried out by overlaying the proteins with their most significant networks and biochemical pathways from previous publications. The identified proteins were additionally classified into different categories according to their function and location using the protein analysis through the evolutionary relationship (PANTHER) classification system (http://www.pantherdb.org).

Statistical Analysis
The 2D-DIGE gel images were uploaded into Progenesis SameSpots software (Nonlinear Dynamics, United Kingdom) and analyzed using an automated spot detection method. The analysis included comparing the samples from the GAMOS and control groups. Although an automatic analysis was performed to detect all the spots across all three gels, each selected spot was verified and manually edited wherever necessary. Normalized volumes were used to identify the differentially expressed spots. A cutoff ratio of ≥1.5-fold was considered significant. Student's t-test was used to calculate statistically significant differences between the groups (p < 0.05 considered statistically significant). Spots that fulfilled the previously mentioned statistical criteria were subjected to further MS analysis. Principal component analysis (PCA) of the log-transformed spot data was performed.

Whole-Exome Sequencing
The OSGEP variant NM_017807.3:c.973C>G (p.Arg325Gly) causing an amino acid change from Arg to Gly at position 325 was detected in the homozygous state in Patient II-8. This variant Frontiers in Genetics | www.frontiersin.org June 2022 | Volume 13 | Article 806190 Numbered spots indicate those identified to be differentially expressed (over 1.5-fold change, p < 0.05) and successfully identified with MALDI-TOF/TOF.
Frontiers in Genetics | www.frontiersin.org June 2022 | Volume 13 | Article 806190 7 was detected in the parents in the heterozygous state. Variant segregation also showed that all healthy siblings were heterozygotes for the variant. Furthermore, other known monogenic causes of nephrotic syndrome or Galloway-Mowat syndrome have been excluded in the exome analysis.

Computational Analysis of the Mutants
The amino acid R325 of OSGEP is evolutionarily highly conserved across species (Supplementary Figure S1), suggesting critical functional implications for protein structure. OSGEP protein modeling was based on human probable tRNA N6-adenosine threonylcarbamoyltransferase (PDB accession number 6GWJ.1.C) crystal structure identity (Supplementary Figure S1). The amino acid changed from large-sized arginine (hydrophilic, positively charged) to small-sized glycine (hydrophobic, neutral) which is close by the main catalytic active sides of OSGEP and was predicted to affect its interaction with tRNA (Braun et al., 2018). The main catalytic active sides of OSGEP are present in the following residues: H109, H113, Y130, N266, G177, E181, N266, and D294 (The UniProt Consortium, 2021). The previously reported disease-causing variant, R325Q, demonstrates a change from arginine (hydrophilic, positively charged) to glutamine (hydrophilic, neutral) at the same amino acid position. These results strongly suggest the pathogenicity of the c.973C >G (p.Arg325Gly) variant in the OSGEP gene. Furthermore, based on the human genome 37 reference, this variant is presumed to be deleterious and "probably damaging," based on in silico protein prediction tools including SIFT and Mutation Taster. Using PolyPhen, the mutation predicted to be probably damaging with the score of 1.000, as well as Align-GVGD, revealed that this variant will most likely interfere with the function. Furthermore, MutationAssessor to assess the evolutionary conservation of the affected amino acid in protein homologs revealed a high score for this variant which suggests that it is likely to be deleterious. The mutation is present in the population gnomAD with an allele frequency of 0.0000040.

Fluorescence Labeling and Two-Dimensional Difference in Gel Electrophoresis
The differences in protein levels between the patients with GAMOS (n = 3) and controls (n = 3) were assessed by 2D-DIGE. Representative fluorescent protein profiles of 2D-DIGE containing Cy3-labeled control and Cy5-labeled GAMOS samples, Cy2-labeled pooled internal control, and a merged Cy3/Cy5 comparison are shown in Figure 3A-D. A total of 1,450 spots were identified on the gels, of which 150 were significantly different (ANOVA, p ≤ 0.05; fold-change ≥1.5) between the GAMOS and control groups ( Figure 3E). The spot patterns were reproducible across all three gels, leading to alignment and further analysis. Cy2-labeling (the internal standard) was included to permit normalization across the complete set of gels and quantitative differential analysis of the protein levels. The 150 spots showing significant difference between the two groups were then manually excised from the preparative gel for protein identification by MS.

Protein Identification by Mass Spectrometry
To further characterize the proteins differentially expressed between patients with GAMOS and controls, PMFs were used. We successfully identified 107 of the 150 protein spots excised from the preparative gel. MALDI-TOF MS identified 97 spots as unique protein sequences and were matched to the SWISS-PROT database entries by Mascot with high confidence scores ( Table 2,  Supplementary Table S2). The sequence coverage of the proteins identified by PMF ranged from 8 to 87%. In a few cases, variants of the same protein were found at several locations on the gel (  Figure 3E). Among the 107 proteins identified, 40 protein spots were upregulated and 67 were downregulated in the samples from patients with GAMOS compared to those in the control group (  Figure 3E). Among the significantly upregulated proteins were RNA-binding protein 6 (up 4.2-fold, p = 7.36E-05), actin, cytoplasmic-1 (up 4.17-fold, p = 0.004), tropomyosin alpha-4 chain (up 3.26-fold, p = 6.05E-04), C18orf34 protein (up 3.10-fold, p = 0.006), macrophage receptor MARCO (up 3.10-fold, p = 0.01), peroxiredoxin-1 (up 3.06-fold, p = 0.004), and the RNA polymerase II transcription subunit 9 (up 3.0-fold, p = 0.006). The significantly downregulated proteins included keratin, type I cytoskeletal 16 (down 5.70-fold, p = 2.86E-06), serpin B12 (down 5.36-fold, p = 9.02E-04), 4trimethylaminobutyraldehyde dehydrogenase (down 4.08-fold, p = 7.97E-05), galectin-1 (down 3.98-fold, p = 5.00E-04), and TGFβ1-induced anti-apoptotic factor 1 (down 3.68-fold, p = 5.85E-05). A complete list of upregulated and downregulated proteins is presented in Table 2. Among the identified proteins, a few proteins, including hexokinase-3, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, nuclear mitotic apparatus protein 1, zinc finger protein 74, and dynein heavy chain 3, were found in more than one spot on the gels, which could be attributed to posttranslational modifications, cleavage by enzymes, or the presence of different protein species.

Principal Component Analysis and Cluster Analysis
PCA was performed using Progenesis SameSpots software to determine and visualize the potential clustering of the proteins that were differentially expressed in the patients with GAMOS compared to the control group. PCA was performed on all 107 spots that exhibited statistically significant changes (ANOVA, p < 0.05) in abundance as identified by MS. The analyses revealed that the two groups clustered distinctly based on different proteins with an 84.2% score (Supplementary Figure S2). The differentially abundant spots showed expression pattern clusters according to their abundant patterns based on a hierarchical clustering analysis (Supplementary Figure S3). The clustering pattern showed that the change in the protein intensities for the selected spots between the GAMOS and control samples was significantly different.

Protein-Protein Interaction Mapping
We next performed protein-protein interaction analysis for the 107 differentially regulated proteins in patients with GAMOS using IPA. The analysis revealed that among 107 proteins, 33 proteins interacted either directly or indirectly via protein networks ( Figure 4A). The software computes a score based on the best fit obtained from the input data set of proteins and the biological functions database to generate a protein-protein interaction network. The generated network is preferentially enriched for proteins with specific and extensive interactions. The interacting proteins are represented as nodes and their biological relationships as a line. Based on the data, three interaction networks were identified for proteins exhibiting differential expression profiles. The highest scoring network (score = 50; Figure 4, Supplementary Figure S4) incorporated 29 proteins. The proposed highestinteraction network pathway was related to cellular assembly and organization, function and maintenance, and tissue development. Only the top pathways are shown in Figure 4A.
The canonical pathways enriched in the current dataset are shown in Figure 4B. These canonical pathways are sorted down to a decreasing log (p-value) of enrichment. The three most interesting enriched canonical pathways included RhoA signaling, actin cytoskeleton signaling, and integrin signaling.

Functional Characterization of the Differentially Expressed Proteins
Following MS analysis, all 107 differentially abundant proteins identified between the GAMOS and control samples were subjected to the PANTHER classification system (http://www. pantherdb.org) for classification according to their function (Supplementary Figure S5A) and location (Supplementary Figure S5B). The dominant functional categories identified were binding proteins (49%) and proteins involved in catalytic activity (28%) (Supplementary Figure S5A). Most proteins showed cellular localization (44%), followed by organellelocalized proteins (26%) (Supplementary Figure S5B).

DISCUSSION
GAMOS is a phenotypically heterogenous disease characterized by a combination of early-onset steroid-resistant nephrotic syndrome and microcephaly with brain anomalies (Galloway and Mowat, 1968;Cohen and Turner, 1994;Braun et al., 2017;Braun et al., 2018). The three siblings (II-1, II-2, and II-8) and their cousin from a consanguineous family share a similar phenotype, including dysmorphic facial features, respiratory distress, and nephrotic syndrome, resulting in massive proteinuria and brain abnormalities. Their phenotypes were similar to those of patients with OSGEP variants reported by Braun et al. (2017), which included microcephaly, severe deformation of the forehead, reduced gyration, diffuse cortical atrophy, focal segmental glomerulosclerosis, and foot process effacement resulting from massive proteinuria (Braun et al., 2017). The homozygous variant, c.973C>G (p.Arg325Gly), in the OSGEP gene identified in Patient II-8 by whole-exome sequencing caused an amino acid change from arginine to glycine, which was presumed to be deleterious and probably damaging based on in silico protein prediction algorithms. While this particular variant has not been described previously in the literature, two different variants that affect the same amino acid residue have been published as disease-causing for Galloway-Mowat syndrome (Braun et al., 2017;Edvardson et al., 2017). Therefore, the variant detected here is classified as "probably pathogenic", according to the American College of Medical Genetics and Genomics (ACMG) recommendations. Retrospective clinical analysis revealed compatibility of the patient's phenotype with the identified variant, and variant segregation showed that all healthy siblings were heterozygotes for the variant.
We identified multiple differentially dysregulated proteins, indicating that OSGEP plays a role in multiple developmental pathways. Thereby, these dysregulated pathways might be involved in GAMOS pathology. For example, the downregulated proteins with the highest GAMOS/control ratio regulate supramolecular fiber organization, cyclic-nucleotide phosphodiesterase activity, modification by a host of symbiont morphology or physiology, and smooth muscle contraction (Supplementary Figure S6). Proteins that showed the highest GAMOS/control ratio were involved in the P2X7 receptor signaling complex, vesiclemediated transport, translocation of SLC2A4 (GLUT4) to the plasma membrane, and phagocytosis (Supplementary Figure  S7). The renal-neurological presentation of GAMOS could be traced to the protein dysregulation found in this study. P2X7 signaling activation, which includes upregulation of ACTB, HSPA8, and HSP90AB1, has been shown to play a significant role in brain development and has been linked to many neurodegenerative, neuroinflammatory, and neurogenic diseases (Sharp et al., 2008;Andrejew et al., 2020). Furthermore, heat shock proteins (HSPA8 and HSP90B1), annexins (ANXA1, ANXA2, and ANXA5), and vesicle-mediated transport proteins (ACTB, CTTN, STXBP3, MARCO, and YWHAZ), which are essential for normal kidney development, are found to be dysregulated and to contribute to the observed nephrotic syndrome (Smoyer et al., 1996;Markoff and Gerke, 2005;Simsek et al., 2008;Chebotareva et al., 2018). Interestingly, none of the deferentially regulated genes described is a member of the KEOPS complex nor is it a known GAMOS-causing or NS-causing gene. Indeed, the deferentially regulated genes that are suggested to be involved in kidney pathology are important during development but are not a known cause of monogenic nephrotic syndrome.
Taken together, the data have suggested that the loss of tRNA N6-adenosine threonylcarbamoyltransferase protein function affects many other essential proteins required for protein folding, protein binding, transport, and catalytic activity.

DATA AVAILABILITY STATEMENT
The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by KSU-IRB. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
MA, RH, and TK conceived and designed the study. MA, MS, FB, and KA were involved in patient recruitment. HB, AM, and AA performed the proteomic laboratory work and data analysis. NS-A and MYH performed the proteomic data and analysis and protein modeling. PGM, SS, VK, and AB-A performed the genetic testing WES and Sanger sequencing and the analysis. MA, HAA, and MH performed full clinical characterization on the patients and wrote the manuscript. IA and DJ involved in neuroradiological description. HIA performed the analysis of the muscle biopsy and the histopathology figure. All authors have read and agreed to the published version of the manuscript.

FUNDING
This project was funded by the National Plan for Science, Technology, and Innovation MAARIFAH, King Abdul Aziz City for Science and Technology, Kingdom of Saudi Arabia, Award Number (5-18-03-001-0010).

ACKNOWLEDGMENTS
We are grateful to the family and study individuals for their contribution.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.806190/ full#supplementary-material Supplementary Figure S1 | OSGEP protein 3D model. (A) Crystallized structure of the human probable tRNA N6-adenosine threonylcarbamoyltransferase (PDB accession number 6GWJ.1.C). (B,C) Protein structure is shown as teal ribbon, while the amino acids at the mutation site are displayed as red stick. The catalytic binding sites of OSGEP are mapped as blue spheres (Residues: H109, H113, Y130, N266, G177, E181, N266, and D294). (D) Surface electrostatic potential surrounding Arg325, with the protruding positive patch generated by the arginine, which is lost in the bottom-right picture (E) after the replacement for glycine. The amino acid substituted from large-sized arginine (hydrophilic, positively charged) to smaller-sized glycine (hydrophobic, neutral) at position 325 which is close by the main catalytic active sides of OSGEP and predicted to affect its interaction with tRNA.
Supplementary Figure